A fundamental discovery by University of Missouri scientists could help solve one of the most frustrating challenges in ...

Researchers from POSTECH and Kyungpook National University have developed a novel inhalable therapeutic delivery system for lung cancer, leveraging mucoadhesive protein nanoparticles inspired by ...

Researchers from POSTECH and Kyungpook National University have developed a novel inhalable therapeutic delivery system for lung cancer, leveraging mucoadhesive protein nanoparticles inspired by ...

Immune Checkpoint Inhibitors and Lung Cancer Treatment. Scientists stated that the discovery of ICSs, particularly the development of antibodies targeting PD-L1 and PD-1, has altered the pathway of ...

In addition to the antimicrobial features, these silver nanoparticles killed various cancer cells, including breast (MCF-7 cells), liver (HepG2 cells), and lung (A549).

Researchers from POSTECH and Kyungpook National University have developed a novel inhalable therapeutic delivery system for lung cancer, leveraging mucoadhesive protein nanoparticles inspired by the ...

Sep 09, 2024: Iron-doped carbon nanoparticles boost cancer treatment with enhanced precision and safety (Nanowerk News) A collaborative research team, led by Prof. WANG Hui and Prof. QIAN Junchao from ...

A new drug combo recently approved by the Food & Drug Administration can halt lung cancer in its treacherous tracks — for over 40% longer than previously possible, a wide-ranging trial funded by ...

Dr. Prantesh Jain and Dr. Joshua K. Sabari explained that there were numerous advances in the non-small cell lung cancer (NSCLC) treatment space following the 2025 ASCO Annual Meeting, highlighting ...

AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat a type of lung cancer, marking the first approval of the therapy in this ...

The FDA has granted fast-track approval to the drug telisotuzumab vedotin (sold as Emrelis) as a first-of-its-kind treatment for certain people who have non-squamous non-small-cell lung cancer.